Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

J Clin Oncol. 2022 Jan 1;40(1):106-107. doi: 10.1200/JCO.21.01754. Epub 2021 Oct 15.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bortezomib
  • Humans
  • Lenalidomide
  • Multiple Myeloma* / drug therapy
  • Secondary Prevention

Substances

  • Bortezomib
  • Lenalidomide